NCT02126358View on ClinicalTrials.gov

Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)

PHASE3CompletedINTERVENTIONAL

Enrollment

290

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Type 2 DiabetesDyslipidemia

Interventions

DRUG

Gemigliptin and/or Rosuvastatin

Trial Locations (1)

Unknown

Severance hospital, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY